Notwithstanding positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. The insurers are typically creating barriers to coverage, including steep cost criteria and prior authorization that hinder user availability. Industry